Anzeige
Mehr »
Freitag, 18.07.2025 - Börsentäglich über 12.000 News
Klinisch validiert. Vertriebsbereit. Und kurz vor der FDA-Zulassung.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N7N8 | ISIN: KYG4818G1010 | Ticker-Symbol: 6IB
Tradegate
17.07.25 | 19:31
9,700 Euro
+2,11 % +0,200
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
INNOVENT BIOLOGICS INC Chart 1 Jahr
5-Tage-Chart
INNOVENT BIOLOGICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,60010,10017.07.
9,75010,00017.07.

Aktuelle News zur INNOVENT BIOLOGICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoNature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma59SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
► Artikel lesen
08.07.CLSA Raises INNOVENT BIO (01801.HK) TP to HKD108.4; Focus on Next-Gen Oncology Franchise6
08.07.Daiwa Lifts INNOVENT BIOs TP to HKD95, Reiterates Rating Buy4
INNOVENT BIOLOGICS Aktie jetzt für 0€ handeln
08.07.CCBI Elevates INNOVENT BIO (01801.HK) TP to $100, Keeps Rating at Outperform3
08.07.HSBC Research Raises INNOVENT BIOs TP to HKD110; Rating Kept Buy3
04.07.INNOVENT BIO (01801): NEXT DAY DISCLOSURE RETURN1
04.07.INNOVENT BIO (01801): COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE1
02.07.Citi Raises INNOVENT BIO's TP to HKD90; New Phase Begins6
30.06.INNOVENT BIO (01801): GRANT OF SHARE OPTIONS AND RESTRICTED SHARES2
30.06.Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide51
27.06.With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs10
27.06.Innovent's Mazdutide receives approval for chronic weight management in China1
27.06.Innovent Biologics' Mazdutide Gets China Approval For Chronic Weight Management375BEIJING (dpa-AFX) - Innovent Biologics, Inc. (IVBXF.OB) announced Friday that China's National Medical Products Administration or NMPA has approved mazdutide for chronic weight management in...
► Artikel lesen
27.06.INNOVENT BIO's Weight Loss Drug Approved For Chronic Weight Mgmt2
27.06.INNOVENT BIO (01801): VOLUNTARY ANNOUNCEMENT - FIRST DUAL GCG/GLP-1 RECEPTOR AGONIST MAZDUTIDE RECEIVED APPROVAL BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ...1
27.06.CN NMPA Approves Innovent Biologics' GLP-1 Weight Loss Drug for Marketing1
26.06.INNOVENT BIO Craters 4%+ in Morning Session on 4.9% Discount to Raise $4.27B in Shr Placement3
26.06.INNOVENT BIO Raises Net Proceeds of $4.27B in Shr Placement at 4.9% Discount2
26.06.INNOVENT BIO (01801): PLACING OF NEW SHARES UNDER GENERAL MANDATE2
25.06.INNOVENT BIO (01801): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 25, 20253
Weiter >>
77 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1